<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20751" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Duloxetine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhaliwal</surname>
            <given-names>Jaberpreet S.</given-names>
          </name>
          <aff>Kaweah Delta Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Spurling</surname>
            <given-names>Benjamin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Molla</surname>
            <given-names>Mohammed</given-names>
          </name>
          <aff>Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaberpreet Dhaliwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Spurling declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Molla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20751.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Duloxetine is a medication used to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain. Off-label uses for duloxetine include chemotherapy-induced peripheral neuropathy and stress urinary incontinence. It is in the Serotonin and norepinephrine reuptake inhibitors (SNRIs) class of medications. This activity describes the indications, mechanism of action, and contraindications for duloxetine as a valuable agent in treating multiple health conditions. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant drug-drug interactions) pertinent for members of the interprofessional team in the treatment of patients with major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, chronic musculoskeletal pain, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for the use of duloxetine.</p></list-item><list-item><p>Describe the most common potential adverse events associated with duloxetine therapy.</p></list-item><list-item><p>Explain the importance of monitoring for patients on duloxetine therapy and summarize key patient counseling points.</p></list-item><list-item><p>Explain how the successful initiation and maintenance of effective therapy with duloxetine requires a well-coordinated interprofessional team approach.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20751&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20751">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20751.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Duloxetine hydrochloride&#x000a0;is a serotonin and norepinephrine reuptake inhibitor (SNRI), first patented in 1990 and marketed in the United States in 2004. It is FDA-approved for&#x000a0;use in the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, chronic musculoskeletal pain, and diabetic peripheral neuropathy. Off-label (non-FDA approved) use for duloxetine includes chemotherapy-induced peripheral neuropathy and stress urinary incontinence in both men and women.<xref ref-type="bibr" rid="article-20751.r1">[1]</xref></p>
        <p>In addition to its general SNRI properties, duloxetine also increases dopamine levels, specifically in the prefrontal cortex. Due to the involvement of the prefrontal cortex in depression, the actions of duloxetine in this region also contribute to its efficacy in the treatment of depression. However, the mechanism of action does not involve the inhibition of dopamine transporters.<xref ref-type="bibr" rid="article-20751.r2">[2]</xref></p>
      </sec>
      <sec id="article-20751.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Duloxetine inhibits serotonin and norepinephrine reuptake, thus combining two therapeutic mechanisms in one agent to treat depression and anxiety. As well, duloxetine enhances dopamine levels within the prefrontal cortex. The mechanism of action behind the increase in dopamine levels involves the inhibition of norepinephrine transporters. These transporters have a significant affinity for dopamine, resulting in the transporter&#x02019;s ability to act on both dopamine and norepinephrine. Therefore, inhibition of norepinephrine transporters can lead to an increase in dopamine. This increase in dopamine specifically occurs in the prefrontal cortex, where dopamine transporters are scarce, and reuptake relies more heavily on norepinephrine transporters.<xref ref-type="bibr" rid="article-20751.r3">[3]</xref></p>
        <p>Duloxetine works to treat various neuropathic and chronic pain states by increasing the activity of noradrenergic and serotonergic neurons in the descending spinal pathway on the dorsal horn. These descending neurons inhibit the activity of dorsal horn neurons, suppressing excessive input from reaching the brain. The hypothesis is that a deficiency in these inhibitory signals results in excess input reaching the brain, which gets perceived as pain.<xref ref-type="bibr" rid="article-20751.r4">[4]</xref></p>
        <p>Of note, duloxetine has no&#x000a0;significant activity for muscarinic, cholinergic, alpha2-adrenergic, or H1 histaminergic receptors.</p>
      </sec>
      <sec id="article-20751.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Duloxetine is&#x000a0;most commonly administered in a capsule form due to good absorption via the oral route, and administration can be with or without food. Duloxetine should not be crushed or chewed. However, studies have shown that duloxetine may remain stable up to 2 hours after being opened and sprinkled on apple juice or apple sauce.</p>
        <p><bold>Management of fibromyalgia</bold>: 30 mg once daily can be given for one week, then the dose may be increased to 60 mg once daily. A titration approach may also be utilized starting with 20 mg daily, then increasing the dose by 20 mg every week, up to 60 mg, as tolerated. Maximum dose: 60 mg/day.<xref ref-type="bibr" rid="article-20751.r5">[5]</xref></p>
        <p><bold>Treatment of generalized anxiety disorder (GAD)</bold>: 60mg can be administered initially, however depending on patient tolerance, 30 mg may be given once daily for one week, then the dose may be increased to 60mg once daily. Though studies have shown no additional benefit to doses above 60 mg/day, some experts have reported benefits when increasing doses over 60 mg/day.</p>
        <p><bold>Treatment of unipolar major depressive disorder (MDD)</bold>: 40 to 60 mg/day can be given in a single or two divided doses. It may be necessary to start at 30mg/day for one week, and then the dose may be increased to 60 mg/day. Maintenance: 60 mg/day. Though studies have shown no additional benefit to doses above 60 mg/day, some experts have reported benefits when increasing doses over 60 mg/day.</p>
        <p><bold>Management of pain associated with diabetic peripheral neuropathy</bold>: 60 mg can be administered initially; however, lower starting doses may be appropriate depending on patient tolerance. Maximum dose: 60 mg/day.</p>
        <p>
<bold>Management of chronic musculoskeletal pain:</bold>
</p>
        <p>Low back pain: 30 mg can be given once daily for one week and increased up to 60 mg once daily as tolerated as an adjunct therapy. Maximum dose: 60 mg/day.&#x000a0;</p>
        <p>Knee pain: 30 mg can be given once daily for one week and increased up to 60 mg once daily as tolerated as an adjunct therapy.<xref ref-type="bibr" rid="article-20751.r6">[6]</xref></p>
      </sec>
      <sec id="article-20751.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Duloxetine has a very low anticholinergic side effect profile; adverse effects of the cardiovascular, gastrointestinal, central nervous system, such as headaches and drowsiness, and fatigue, are more common.<xref ref-type="bibr" rid="article-20751.r1">[1]</xref><xref ref-type="bibr" rid="article-20751.r6">[6]</xref></p>
        <p>Serious adverse effects of duloxetine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Suicidality</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome</p>
          </list-item>
          <list-item>
            <p>Hepatoxicity</p>
          </list-item>
          <list-item>
            <p>Mania</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p>
          </list-item>
          <list-item>
            <p>Hyponatremia</p>
          </list-item>
        </list>
        <p>Common adverse effects of duloxetine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Xerostomia</p>
          </list-item>
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Chane in libido</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Decreased appetite</p>
          </list-item>
          <list-item>
            <p>Tremor</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction<xref ref-type="bibr" rid="article-20751.r1">[1]</xref><xref ref-type="bibr" rid="article-20751.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20751.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Duloxetine is contraindicated in patients with concurrent or recent (within two weeks) therapy with monoamine oxidase (MAO) inhibitors, uncontrolled angle-closure glaucoma, or hypersensitivity to duloxetine. Duloxetine should also be avoided in patients with liver failure or severe renal dysfunction. Clinicians should also avoid using duloxetine in patients receiving treatment with linezolid or intravenous methylene blue due to an increased risk of serotonin syndrome.<xref ref-type="bibr" rid="article-20751.r1">[1]</xref></p>
        <p>
<bold>Precautions and Warning in Special Population</bold>
</p>
        <p>
<bold>Pregnant Patients</bold>
</p>
        <p>Duloxetine is FDA pregnancy category C, which means risk to fetal development cannot be ruled out. In animal reproductive studies, duloxetine demonstrated adverse effects on embryo/fetal development. Therefore, the clinician&#x000a0;should only prescribe duloxetine if the potential benefits justify the potential risk to the fetus.</p>
        <p>
<bold>Breastfeeding Women</bold>
</p>
        <p>Duloxetine is excreted in breast milk and may produce effects in the nursing infant. Some studies show the relative infant dose (RID) of duloxetine to be 2.3%. RID is the dose received via breast milk relative to the mother&#x02019;s dose. A RID below 10% is acceptable when breastfeeding. Some sources recommend breastfeeding only if the RID is less than 5% if the mother is on psychotropic medication. Regardless, an infant breastfed by a mother receiving duloxetine requires monitoring for behavior changes, sleep disturbance, feeding changes, growth, and neurodevelopment.<xref ref-type="bibr" rid="article-20751.r7">[7]</xref></p>
        <p>
<bold>Elderly</bold>
</p>
        <p>SSRIs and SNRIs have correlations with several cases of clinically significant hyponatremia in elderly adults. Caution is necessary when prescribing duloxetine in the geriatric population. However, dosage adjustment based on the age of the patient is not required.<xref ref-type="bibr" rid="article-20751.r8">[8]</xref></p>
      </sec>
      <sec id="article-20751.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should check blood pressure and vitals before initiating therapy and routinely after that. Monitor for changes in suicidal ideation, especially when starting treatment, altering the dose, and after discontinuation of therapy. Monitor for worsening depression, behavioral changes such as mania, and withdrawal symptoms from abrupt discontinuation. Patients should be monitored for abnormal bleeding as duloxetine may impair platelet aggregation. Caution should be exercised when using anticoagulants or antiplatelet medications along with duloxetine therapy. Laboratory workup should include monitoring serum creatinine, blood urea nitrogen(BUN), transaminase levels, blood glucose levels, and HgbA1c in diabetic patients. Sodium levels require follow-up when prescribing duloxetine in the geriatric population.<xref ref-type="bibr" rid="article-20751.r1">[1]</xref></p>
      </sec>
      <sec id="article-20751.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Fatal outcomes have occurred with overdoses at as low as 1000 mg. Signs and symptoms of overdose include serotonin syndrome, seizures, coma, somnolence,&#x000a0;syncope, tachycardia, autonomic instability, diarrhea, and vomiting. Signs of serotonin syndrome include agitation, restlessness, disorientation, diaphoresis, hyperthermia, tachycardia, nausea, vomiting, tremor, muscle rigidity, hyperreflexia, myoclonus, dilated pupils, dry mucous membranes, and increased bowel sounds. Clonus and hyperreflexia are particularly common in serotonin syndrome.</p>
        <p>There is no antidote to duloxetine overdose. If the patient is presenting with serotonin syndrome, cyproheptadine and cooling measures may be considered. Patients with abnormal vital signs need monitoring, and severe cases may warrant ICU-level of care.<xref ref-type="bibr" rid="article-20751.r9">[9]</xref><xref ref-type="bibr" rid="article-20751.r10">[10]</xref></p>
      </sec>
      <sec id="article-20751.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Antidepressants including duloxetine may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults who have a major depressive disorder and other psychiatric disorders. Close observation and routine follow-up by the healthcare team is essential in ensuring medication compliance and patient safety.</p>
        <p>When&#x000a0;a patient is started on&#x000a0;duloxetine therapy, all the interprofessional team members, including clinicians, mid-level practitioners, specialists, nurses, social workers, and pharmacists, should be involved in patient care. The pharmacist should perform a thorough medication reconciliation to preclude any drug interactions and verify that dosing is appropriate. A psychiatric health specialist nurse will assist with patient counseling regarding administration and monitor the patient on follow-up visits. If there are any warning symptoms or concerns, the pharmacist and nurse should inform the prescriber promptly. Any social workers or other mental health counselors also need to be included in the sharing of information. This type of interprofessional team&#x000a0;approach&#x000a0;can&#x000a0;ensure&#x000a0;optimal patient outcomes with minimal adverse events.</p>
      </sec>
      <sec id="article-20751.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20751&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20751">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20751/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20751">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20751.s11">
        <fig id="article-20751.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Duloxetine molecule Contributed by the U.S. National Library of Medicine (https://pubchem.ncbi.nlm.nih.gov/compound/duloxetine#section=Chemical-Vendors)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Duloxetine__Molecule" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20751.s12">
        <title>References</title>
        <ref id="article-20751.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koesters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Nos&#x000e8;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purgato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Omori</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Trespidi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Duloxetine versus other anti-depressive agents for depression.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Oct</month>
            <day>17</day>
            <volume>10</volume>
            <fpage>CD006533</fpage>
            <pub-id pub-id-type="pmid">23076926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>e0194501</fpage>
            <pub-id pub-id-type="pmid">29558528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wiltse</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Mallinckrodt</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Demitrack</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bitter</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-70</page-range>
            <pub-id pub-id-type="pmid">15589385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furutani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Funatsu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Effects of pregabalin and duloxetine on neurotransmitters in the dorsal horn of the spinal cord in a rat model of fibromyalgia.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>827</volume>
            <fpage>117</fpage>
            <page-range>117-124</page-range>
            <pub-id pub-id-type="pmid">29530591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Behling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niemira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>293</fpage>
            <page-range>293-301</page-range>
            <pub-id pub-id-type="pmid">30464796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wohlreich</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mallinckrodt</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watkin</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.</article-title>
            <source>Depress Anxiety</source>
            <year>2007</year>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-52</page-range>
            <pub-id pub-id-type="pmid">16845641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The safety of duloxetine during pregnancy and lactation.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>e1423</fpage>
            <page-range>e1423-7</page-range>
            <pub-id pub-id-type="pmid">25551238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alibegovi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kari&#x0017e;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Volav&#x00161;ek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fatal overdose with a combination of SNRIs venlafaxine and duloxetine.</article-title>
            <source>Forensic Sci Med Pathol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-261</page-range>
            <pub-id pub-id-type="pmid">30796754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20751.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpi-Abadie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">24358002</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
